Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE: LLY) is gaining ground in the GLP-1 market, edging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback